The Future of Mobile Health: Mobile Adoption, mHealth and Mobile Marketing

Manhattan ResearchGlobal pharmaceutical and healthcare market research company Manhattan Research releases its latest consumer marketing analysis titled "The Future of Mobile Health: Mobile Adoption, mHealth and Mobile Marketing" as part of its Cybercitizen Health™ v8.0 market research and strategic advisory service.

"The Future of Mobile Health" gives an in-depth look at the growing mHealth market, which now stands at over 10 million U.S. adults using mobile devices for health information, and contains market data, charts, and analysis for key demographic and condition-specific trends. It also discusses how companies are currently using mobile health applications, mobile marketing opportunities and strategies, and insight to where the market is heading.

According to the analysis, consumers with smartphones tend to be the most interested in mobile health applications for weight loss, as well as prescription drug tracking. The WebMD Mobile application for the iPhone, which provides information on every day health topics and on symptoms, drugs or treatments and basic first aid, has seen over 200,000 downloads since launching in November 2008. Johnson & Johnson also recently launched the CareConnector iPhone application as an accessory to its caregiver support site, StrengthForCaring.com.

"Mobile Health, or mHealth, is exploding around the globe, with programs for remote monitoring, disaster preparedness, treatment compliance, and education appearing in countries where traditional forms of communication, such as television, mail, or even the Internet, were not available," said Meredith Abreu Ressi, author of the analysis and Vice President of Research at Manhattan Research. "In the U.S., there are similar opportunities - along with the ability to explore mobile marketing initiatives such as mCoupons, opt-in text message databases, or short code DTC response. But developing content for the mobile Web has its own set of rules, so simply repurposing existing Web sites for mobile access is insufficient."

Analysis Outline
Title: The Future of Mobile Health: Mobile Adoption, mHealth, and Mobile Marketing

  • Mobile Adoption in the U.S.
  • mHealth and Mobile Marketing Today
    • mHealth in the U.S.
    • A Look Around the iPhone App Store
  • The Future of mHealth and Mobile Marketing
    • Benefits of Mobile Health Initiatives
    • Opportunities for Mobile Health (mHealth) in the U.S.
    • Mobile Marketing Opportunities
    • Key Learnings and Action Items

For an excerpt from the analysis and more information about its contents, please visit: http://www.manhattanresearch.com/products/Research_Modules/Consumer/future-of-mobile-health.aspx

Accessing the "The Future of Mobile Health" analysis is immediately available to subscribers of Manhattan Research's Cybercitizen Health™ v8.0 market research and strategic advisory service. For more information about becoming a subscriber to this service and gaining access to the in-depth consumer market data and analysis, visit http://www.manhattanresearch.com/cch.

About Cybercitizen Health™ v8.0
Cybercitizen Health™ v8.0 was fielded in Q3 2008 among 8,714 U.S. adults (ages 18+). This consumer market research and strategic advisory service focuses on how consumers use new media and technology for health and its impact on treatment and product decisions. For topics and available therapeutic segmentations (100+), please visit http://www.manhattanresearch.com/cch.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com.

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...